MREO News and Press, Mereo BioPharma Group From 10/23/23

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial ...

2023-10-23 08:21:00 ET Textainer Group Holdings  ( TGH ) +43% . Mynaric  ( MYNA ) +17% . Navios Maritime Holdings ( NM ) +17% to buy N Logistics in $2.28/share all-cash deal. Next. ( EGOX ) +16% . Harpoon Therapeutics ( HARP ) ...

2023-10-16 13:36:37 ET Gainers: Tempest Therapeutics ( TPST ) +98% . Momentus ( MNTS ) +51% . PCTEL ( PCTI ) +47% . Almacenes Exito ( EXTO ) +33% . Mereo Biopharma Group Plc ( MREO ) +30% . Rani Therapeutics Holdings ( RANI...

2023-10-16 12:17:55 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Processa Pharmaceuticals Inc (NASDAQ: PCSA), Mereo BioPharma Group PLC (NASDAQ: MREO), Tempest Therape...

2023-10-16 10:00:00 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further...

2023-10-16 09:56:56 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; LQR House Inc (NASDAQ: LQR), Better Therapeutics Inc (NASDAQ: BTTX), Mereo BioPharma Group PLC (NASDAQ: MREO)...

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Cal...

NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 ...

2023-09-21 18:10:58 ET Summary Mereo BioPharma's extended financial runway and reduced R&D spend improve its short-term risk profile. Diverse pipeline, led by setrusumab and alvelestat, offers long-term growth but awaiting key clinical readouts. The company's etigilimab co...

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...